Information Provided By:
Fly News Breaks for January 9, 2020
Jan 9, 2020 | 08:00 EDT
JPMorgan analyst Eric Joseph raised his price target for Karyopharm Therapeutics to $27 from $23 ahead of the Phase 3 BOSTON readout this quarter. The analyst sees a high probability of success and a favorable reward/risk profile for the shares. He keeps an Overweight rating on the name.